

N-[(*E*)-Anthracen-9-ylmethylidene]-3,4-dimethyl-1,2-oxazol-5-amine

Abdullah M. Asiri,^{a,b} Abdulrahman O. Al-Youbi,^a Salman A. Khan^a and M. Nawaz Tahir^{c*}

^aDepartment of Chemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, PO Box 80203, Saudi Arabia, ^bThe Center of Excellence for Advanced Materials Research, King Abdulaziz University, Jeddah 21589, PO Box 80203, Saudi Arabia, and ^cUniversity of Sargodha, Department of Physics, Sargodha, Pakistan
Correspondence e-mail: dmntahir_uos@yahoo.com


Received 4 November 2011; accepted 24 November 2011

Key indicators: single-crystal X-ray study; $T = 296$ K; mean $\sigma(C-C) = 0.002$ Å; R factor = 0.044; wR factor = 0.130; data-to-parameter ratio = 15.2.

In the title compound, $C_{20}H_{16}N_2O$, an intramolecular C–H···N forms an *S*(6) ring motif. In the crystal, the molecules are stacked with their anthracene ring planes in sheets along [100].

Related literature

For applications of compounds containing azomethine groups, see: Khuhawar *et al.* (2004). Schiff base compounds demonstrate antibacterial (Asiri & Khan, 2010), antitumor activity (Saxena & Tandon, 1983) and anti-HIV activity (Pandeya *et al.*, 1999). For related structures, see: Asiri *et al.* (2011a,b). For graph-set notation, see: Bernstein *et al.* (1995).

**Experimental***Crystal data*

$C_{20}H_{16}N_2O$
 $M_r = 300.35$
Monoclinic, $C2/c$
 $a = 22.4919$ (14) Å

$b = 6.1666$ (4) Å
 $c = 22.6801$ (13) Å
 $\beta = 102.015$ (2)°
 $V = 3076.8$ (3) Å³

$Z = 8$
Mo $K\alpha$ radiation
 $\mu = 0.08$ mm⁻¹

$T = 296$ K
 $0.32 \times 0.24 \times 0.22$ mm

Data collection

Bruker KAPPA APEXII CCD diffractometer
Absorption correction: multi-scan (*SADABS*; Sheldrick, 2004)
 $T_{min} = 0.975$, $T_{max} = 0.980$

12925 measured reflections
3193 independent reflections
2381 reflections with $I > 2\sigma(I)$
 $R_{int} = 0.028$

Refinement

$R[F^2 > 2\sigma(F^2)] = 0.044$
 $wR(F^2) = 0.130$
 $S = 1.04$
3193 reflections

210 parameters
H-atom parameters constrained
 $\Delta\rho_{\text{max}} = 0.26$ e Å⁻³
 $\Delta\rho_{\text{min}} = -0.21$ e Å⁻³

Table 1

Hydrogen-bond geometry (Å, °).

$D-\text{H}\cdots A$	$D-\text{H}$	$\text{H}\cdots A$	$D\cdots A$	$D-\text{H}\cdots A$
C2—H2···N1	0.93	2.20	2.840 (2)	125

Data collection: *APEX2* (Bruker, 2009); cell refinement: *SAINT* (Bruker, 2009); data reduction: *SAINT*; program(s) used to solve structure: *SHELXS97* (Sheldrick, 2008); program(s) used to refine structure: *SHELXL97* (Sheldrick, 2008); molecular graphics: *ORTEP-3 for Windows* (Farrugia, 1997) and *PLATON* (Spek, 2009); software used to prepare material for publication: *WinGX* (Farrugia, 1999) and *PLATON*.

The authors would like to thank the Chemistry Department, King Abdulaziz University, Jeddah, Saudi Arabia, for providing research facilities.

Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: FK2045).

References

- Asiri, A. M. & Khan, S. A. (2010). *Molecules*, **15**, 6850–6858.
- Asiri, A. M., Khan, S. A. & Tahir, M. N. (2011a). *Acta Cryst. E* **67**, o2163.
- Asiri, A. M., Khan, S. A. & Tahir, M. N. (2011b). *Acta Cryst. E* **67**, o2305.
- Bernstein, J., Davis, R. E., Shimoni, L. & Chang, N.-L. (1995). *Angew. Chem. Int. Ed. Engl.* **34**, 1555–1573.
- Bruker (2009). *APEX2* and *SAINT*. Bruker AXS Inc., Madison, Wisconsin, USA.
- Farrugia, L. J. (1997). *J. Appl. Cryst.* **30**, 565.
- Farrugia, L. J. (1999). *J. Appl. Cryst.* **32**, 837–838.
- Khuhawar, M. Y., Mughal, M. A. & Channar, A. H. (2004). *Eur. Polymer J.* **40**, 805–809.
- Pandeya, S. N., Sriram, D., Nath, G. & Clercq, E. De. (1999). *Pharm. Acta Helv.* **74**, 11–17.
- Saxena, A. & Tandon, J. P. (1983). *Cancer Lett.* **19**, 73–76.
- Sheldrick, G. M. (2004). *SADABS*. University of Göttingen, Germany.
- Sheldrick, G. M. (2008). *Acta Cryst. A* **64**, 112–122.
- Spek, A. L. (2009). *Acta Cryst. D* **65**, 148–155.